Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Thrombosis and Thrombolysis

• Publication date

  2015-01-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11239-015-1167-9PMID 25586208
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention

  2016cited by this paper
• Diagnosis and Management of Acute Intracerebral Hemorrhage.

  2016cited by this paper
• Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate

  2015cited by this paper
• Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation

  2015cited by this paper
• Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates – in vitro studies with steady and circulating human blood.

  2015cited by this paper
• Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers

  2014influential reference
• Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis.

  2014cited by this paper
• Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects

  2014cited by this paper
• Abstract 18544: Bloods Loss in Dabigatran Anticoagulated Pigs With Polytrauma is Significantly Reduced by Early Therapy With Activated and Non-activated Prothrombin Complex Concentrates

  2014cited by this paper
• Abstract 18218: In Vitro Characterization of Andexanet Alfa (PRT064445), a Specific fXa Inhibitor Antidote versus Aripazine (PER977), a Non-specific Reversal Agent

  2014cited by this paper
• Abstract 14657: Andexanet-alfa and PER977 (Arapazine) Correct Blood Loss in a Rabbit Liver Laceration Model - Only Andexanet Reverses Markers of fXa-mediated Anticoagulation

  2014cited by this paper
• A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors

  2014cited by this paper
• Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography.

  2014cited by this paper
• Reversal of target-specific oral anticoagulants.

  2014cited by this paper
• Measurement and Reversal of Prophylactic and Therapeutic Peak Levels of Rivaroxaban

  2014cited by this paper
• A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens.

  2014cited by this paper
• Ex vivo reversal of the anticoagulant effects of edoxaban.

  2014cited by this paper
• Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.

  2014cited by this paper
• Use of PER977 to reverse the anticoagulant effect of edoxaban.

  2014cited by this paper
• Reversal of Dabigatran-induced Bleeding by Coagulation Factor Concentrates in a Rat-tail Bleeding Model and Lack of Effect on Assays of Coagulation

  2014cited by this paper
• Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.

  2014cited by this paper
• A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

  2013influential reference
• Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates

  2013influential reference
• The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran

  2013cited by this paper
• Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban

  2013influential reference
• In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban

  2013cited by this paper
• Reversal of novel oral anticoagulants in patients with major bleeding

  2013cited by this paper
• Effective elimination of dabigatran by haemodialysis

  2013cited by this paper
• Abstract 17765: A Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Healthy Male Volunteers

  2013cited by this paper
• Abstract WP273: Reversal of Dabigatran’s Anticoagulant Activity in the Monkey by a Specific Antidote and Pharmacokinetic and Pharmacodynamic Modeling

  2013cited by this paper
• Abstract 10: Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Pharmacokinetic and Pharmacodynamic Study of PRT064445, a Universal Antidote for Factor Xa Inhibitors

  2013cited by this paper
• Abstract WP261: In Vitro Characterization, Pharmacokinetics and Reversal of Supratherapeutic Doses of Dabigatran-Induced Bleeding in Rats by a Specific Antibody Fragment Antidote to Dabigatran

  2013cited by this paper
• Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.

  2013influential reference
• Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.

  2013cited by this paper
• Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate

  2012cited by this paper
• Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran

  2012cited by this paper
• Use of point‐of‐care testing for plasma therapy

  2012cited by this paper
• Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit Model

  2012cited by this paper
• Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model

  2012cited by this paper
• Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban

  2012influential reference
• Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents

  2011influential reference
• Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor Dabigatran

  2011cited by this paper
• Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists

  2011cited by this paper
• DABIGATRAN ANTICOAGULANT ACTIVITY IS NEUTRALIZED BY AN ANTIBODY SELECTIVE TO DABIGATRAN IN IN VITRO AND IN VIVO MODELS

  2011cited by this paper
• Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects

  2011cited by this paper
• Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

  2011cited by this paper
• Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate

  2010cited by this paper
• Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

  2010cited by this paper
• Desmopressin Reduces Transfusion Needs after Surgery: A Meta-analysis of Randomized Clinical Trials

  2008cited by this paper
• Coagulation factor concentrates: past, present, and future.

  2007cited by this paper
• Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity

  2004cited by this paper
• Late-Breaking Clinical Trial Abstracts

  2002cited by this paper
• Safety of factor VIII inhibitor bypass activity (FEIBA®): 10‐year compilation of thrombotic adverse events

  2002cited by this paper

• A Knowledge and Practice Survey Among Dentists in Saudi Arabia Analysing Myths and Misconceptions in Dentistry and Oral Surgery: What Do Dentists Believe?

  2023cites this paper
• Impact of preoperative antiplatelet / anticoagulant therapy on postoperative bleeding rate in anorectal surgery. Analysis of a high-volume proctologic and pelvic floor clinical center

  2023cites this paper
• Lower GI Hemorrhage

  2021cites this paper
• Efficacy and Safety of Andexanet Alfa for Bleeding Caused by Factor Xa Inhibitors: A Systematic Review and Meta-Analysis

  2021influential citation
• Neurointensive Care Unit: Clinical Practice and Organization

  2020influential citation
• Emergency Management of Acute Intracerebral Hemorrhage

  2020cites this paper
• Anticoagulant-associated intracerebral hemorrhage

  2020cites this paper
• Reversión de anticoagulantes orales directos: una perspectiva desde Urgencias

  2020cites this paper
• Security profile of direct anticoagulants. Preferred use in atrial fibrillation

  2019cites this paper
• WITHDRAWN: Anticoagulant-associated intracerebral hemorrhage

  2019cites this paper
• Management of Bleeding Associated With Anticoagulation

  2019cites this paper
• Security profile of direct anticoagulants. Preferred use in atrial fibrillation.

  2019cites this paper
• Andexanet alfa for the treatment of hemorrhage

  2018cites this paper
• How can we reverse bleeding in patients on direct oral anticoagulants?

  2018cites this paper
• Exploring the effect of factor Xa inhibitors on rotational thromboelastometry: a case series of bleeding patients

  2018cites this paper
• Management of Diverticular Hemorrhage: Catching That Culprit Diverticulum Red-Handed!

  2018cites this paper
• Compartment syndrome secondary to an atraumatic gastrocnemius tear in a patient on NOACs: presentation and complications of treatment

  2018cites this paper
• Managing Nonoperable Intracranial Bleeding Associated With Apixaban: A Series of 2 Cases

  2018cites this paper
• Management of the Trauma Patient on Direct Oral Anticoagulants

  2018cites this paper
• Pharmacologic Reversal Agents

  2018cites this paper
• Management of Oral Anticoagulant-associated Intracerebral Hemorrhage

  2018cites this paper
• How I manage patients with anticoagulation-associated bleeding or urgent surgery.

  2018cites this paper
• A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2.

  2018cites this paper
• Management of direct oral anticoagulant associated bleeding: Results of a multinational survey.

  2018cites this paper
• Evaluation of the Use of Low-Dose 4-Factor Prothrombin Complex Concentrate in the Reversal of Direct Oral Anticoagulants in Bleeding Patients

  2018cites this paper
• Dabigatran Reversal with Idarucizumab.

  2017cites this paper
• Review of the Pharmacology of the Emerging Possibilities of the Direct Oral Anticoagulants' Reversal.

  2017cites this paper
• The Success of Sinister Right-Handers in Baseball.

  2017cites this paper
• Massive Blood Loss

  2017cites this paper
• Point-of-Care Coagulation Tests Monitoring of Direct Oral Anticoagulants and Their Reversal Therapy: State of the Art

  2017cites this paper
• The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran: comment

  2017cites this paper
• Idarucizumab for urgent reversal of dabigatran for heart transplant: A case report

  2017cites this paper
• 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.

  2017cites this paper
• Direct oral anticoagulants and their clinical management

  2017cites this paper
• The Anticoagulated trauma patient in the age of the direct oral anticoagulants: a Canadian perspective

  2017cites this paper
• Measurement and reversal of the direct oral anticoagulants.

  2017cites this paper
• Assessment of the Effects of Antithrombotic Drugs

  2016cites this paper
• Perioperative Management of the Direct Oral Anticoagulants: A Case-Based Review.

  2016cites this paper
• Reversal Agents for the Direct Oral Anticoagulants.

  2016cites this paper
• Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention

  2016cites this paper
• Managing reversal of direct oral anticoagulants in emergency situations

  2016influential citation
• Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants

  2016cites this paper
• ACG Clinical Guideline: Management of Patients With Acute Lower Gastrointestinal Bleeding

  2016cites this paper
• New Oral Anticoagulants and Their Reversal Agents

  2016cites this paper
• Reversal of dabigatran by idarucizumab: when and how?

  2016cites this paper
• NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank.

  2016cites this paper
• Widening the path and window of opportunity for FDA approval of non-vitamin K oral anticoagulant specific antidotes and reversal agents

  2016cites this paper
• How to effectively manage the event of bleeding complications when using anticoagulants

  2016cites this paper
• An update on the pharmaceutical management of thrombosis

  2016cites this paper
• Current knowledge on assessing the effects of and managing bleeding and urgent procedures with direct oral anticoagulants.

  2016cites this paper
• Pharmacological thromboprophylaxis and total hip or knee replacement.

  2016cites this paper
• Direct oral anticoagulants and the bleeding patient

  2016cites this paper
• A Case of Fatal Bleeding Following Emergency Surgery on an Ascending Aorta Intramural Hematoma in a Patient Taking Dabigatran.

  2016cites this paper
• Diagnosis and Management of Acute Intracerebral Hemorrhage.

  2016cites this paper
• Blutungsmanagement bei DOAK – Stellenwert der Antidote

  2016cites this paper
• Novel Oral Anticoagulants for the Treatment of Venous Thromboembolism in Cancer Patients

  2016cites this paper
• Antidotes for direct oral anticoagulants

  2016cites this paper
• Which antidotes are available for the novel oral anticoagulants?

  2016cites this paper
• Non-vitamin K antagonist oral anticoagulant reversal: hope is on the horizon.

  2016cites this paper
• Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options

  2016cites this paper
• Management of Bleeding With Non–Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents

  2016cites this paper
• Monitoring and reversal of direct oral anticoagulants.

  2015cites this paper
• Direct Oral Anticoagulants

  2015cites this paper
• Changing paradigms in the management of deep vein thrombosis

  2015cites this paper
• Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re‐appraisal

  2015cites this paper
• Antidotes to non-vitamin K oral anticoagulants: necessary or not?

  2015cites this paper
• Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review

  2015cites this paper
• A Systems Pharmacology Model for Predicting Effects of Factor Xa Inhibitors in Healthy Subjects: Assessment of Pharmacokinetics and Binding Kinetics

  2015cites this paper
• Anticoagulation Management

  2015cites this paper
• Idarucizumab: First Global Approval

  2015cites this paper